Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why now might be the time to invest.

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Eli Lilly is buying a new drug and lowering ... drugs from both Novo Nordisk and Hims & Hers Health. Lower prices, raise market share. It's as simple as that -- and good enough for a 2.6% stock ...

Per-share earnings for the quarter were $5.32 ... But there’s a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +27.4%.